Search Results

Recipharm announces that it has this morning acquired 4,881,437 Consort Shares, representing 9.9 per cent. of the existing issued share capital of Consort Medical, at 1,010 pence per share and a further 118,563 Consort Shares, representing 0.2 per cent. of the existing issued share capital of Consort Medical at 1,000 pence per share.

Recipharm announced on 4 February 2020 that the offer to acquire Consort Medical plc had become unconditional in all respects and will remain open for acceptances for a further 14 days, until 18 February 2020.

BD, a leading global medical technology company, and a consortium of health care institutions in Denmark have innovated a method to recycle used blood collection tubes without compromising hygiene, safety or quality of the material.

Heart Rhythm Clinical and Research Solutions and the Real World Evidence Consortium have enrolled the first patient in the REView of ProcEdural FactoRs and Outcomes after Atrial Fibrillation Ablation with Active Esophageal COOLing study.

Recipharm AB and Consort Medical plc have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort, a leading global drug delivery and device company and integrated contract development and manufacturing organisation